Low-dose cytosine-arabinoside in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Ten AML- and two MDS-patients in whom conventional chemotherapy was contraindicated or ineffective were treated with low dose ARA-C, 10 mg/m2 per 12hS.C. for 2-4 weeks. Seven patients obtained a complete and two a partial remission. Our findings suggest that low dose ARA-C may act both by induction of differentiation and/or inhibition of proliferation.
D000328:Adult; D000368:Aged; D001855:Bone Marrow Diseases / Q000188:drug therapy*; D001856:Bone Marrow Examination; D003561:Cytarabine / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D011087:Polycythemia Vera / Q000150:complications
D003561:Cytarabine